October 2017 - Pharma Strategies | Zimbabwe

Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review

Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality
Pegfilgrastim is a long-acting version of oncology medicine filgrastim — Sandoz is the European market leader for filgrastim
Sandoz is the global leader in biosimilars, with five biosimilars marketed worldwide and a leading global pipeline, including three biosimilars currently under EMA review

Holzkirchen, October 27, 2017 – Sandoz, a Novartis Division, and the global leader in biosimilars …

Net sales grew 2% (cc[1], +2% USD), with growth in all divisions:
- Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications
- Entresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansion
- Excluding Gleevec/Glivec, Oncology grew 11% (cc)
- Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care
- Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure

Net sales grew 2% (cc[1], +2% USD), with growth in all divisions:
- Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications
- Entresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansion
- Excluding Gleevec/Glivec, Oncology grew 11% (cc)
- Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care
- Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure